Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Very Bullish +80

Barclays Lifts PT on Edwards Lifesciences Corporation (EW) Following Q1 Earnings

AI-generated analysis

πŸ“ˆ Barclays raised its price target on Edwards Lifesciences (EW) to $110 from $104, maintaining an Overweight rating after Q1 earnings.

πŸ’° Fiscal Q1 sales increased 16.7% year-over-year to $1.65 billion on a GAAP basis.

🌍 Sales in Europe and the United States specifically showed gains in the most recent quarter.

❀️ TAVR (Transcatheter Aortic Valve Replacement) sales jumped 14.4% to $1.20 billion, with constant currency growth of 11%.

πŸ”§ TMTT (Transcatheter Mitral and Tricuspid Therapies) sales reached $173 million, driven by repair and replacement procedures.

πŸ“ˆ Edwards Lifesciences raised its fiscal 2026 constant currency sales growth guidance to between 9% and 11%, up from 8-10%.

πŸ’Ή The company also increased its adjusted EPS guidance midpoint range for FY26 to $2.95-$3.05 from a previous $2.90-$3.05.

πŸ—οΈ Operations are segmented by geography into the United States, Europe, Japan, and Rest of World.

πŸ’‘ Business units focus on Transcatheter Aortic Valve Replacement, Mitral/Tricuspid Therapies, Surgical Structural Heart, and Critical Care.

πŸ“’ Jim Cramer noted that Edwards Lifesciences is currently in a "Good Zone" regarding its market position.

πŸ₯ The company specializes in patient-focused medical innovations for heart disease and critical care monitoring.

πŸ€– Analysts at Insider Monkey believe certain AI stocks offer greater upside potential than EW despite positive earnings.

Bullish Signals
  • Barclays raised the price target for Edwards Lifesciences Corporation (NYSE:EW) to $110 from $104, reaffirming an Overweight rating following strong Q1 earnings.
  • Fiscal Q1 sales rose 16.7% year-over-year to $1.65 billion, while constant currency sales grew 12.7%, demonstrating robust revenue expansion.
  • TAVR sales specifically surged 14.4% to $1.20 billion with constant currency growth of 11.0%, highlighting demand in its core structural heart business.
  • The company successfully raised its FY26 constant currency sales growth guidance to a range of 9% to 11%, upgrading from the previous expectation of 8% to 10%.
  • Edwards Lifesciences also increased its FY26 adjusted EPS guidance midpoint, expanding the forecasted range to $2.95 to $3.05 from the prior $2.90 to $3.05.
  • Share gains were reported in both Europe and the United States during the quarter, indicating positive international performance alongside domestic strength.
Risk Factors
  • Despite the upgrade, the article explicitly argues that 'certain AI stocks offer greater upside potential and carry less downside risk' compared to Edwards Lifesciences.
  • The piece suggests Edwards Lifesciences is not as attractive in the current environment, directing readers toward an 'undervalued AI stock' for better short-term returns under Trump-era tariffs.
Full Analysis
Barclays raised its price target on Edwards Lifesciences Corporation (NYSE: EW) to $110 from $104 in a research note published on April 27, reaffirming its "Overweight" rating for the medical device stock. This positive adjustment followed the company's fiscal first-quarter earnings release on April 23, which highlighted share gains across Europe and the United States. In the quarter, Edwards reported a significant increase in overall sales, with fiscal Q1 revenue rising 16.7% to $1.65 billion, while constant currency sales grew by 12.7%. The financial performance was particularly strong within the Transcatheter Aortic Valve Replacement (TAVR) segment, where sales increased 14.4% to reach $1.20 billion, with constant currency growth of 11.0%. Edwards also noted that fiscal Q1 sales for Transcatheter Mitral and Tricuspid Therapies (TMTT) reached $173 million, driven by repair and replacement therapies. Capitalizing on these positive operational results and market performance, the company upgraded its guidance for fiscal year 26, projecting constant currency sales growth between 9% and 11%, up from the previous range of 8% to 10%. Additionally, Edwards raised the midpoint of its adjusted EPS guidance for FY26 to a new range of $2.95 to $3.05, extending the prior range of $2.90 to $3.05. Edwards Lifesciences continues to focus on patient-centered medical innovations for heart disease and critical care monitoring, with product lines categorized into Transcatheter Aortic Valve Replacement, TMTT, Surgical Structural Heart, and Critical Care segments. The company operates across four geographical regions: the United States, Europe, Japan, and Rest of the World. While the article notes Barclays' bullish stance and highlights Jim Cramer's observation that Edwards is in a "good zone," it also includes a disclaimer stating that Yahoo Finance is not a broker-dealer or investment adviser, alongside a separate promotional segment suggesting alternative AI stocks for specific market trends.